
Stakeholder Response Form CRG Product Testing

Please complete one response form per consultation document that you wish to provide comments on.

Date	24/7/18
Respondent's Name	Paul Alexander
Respondent's Organisation	RCR
Replying on behalf of organisation?	Yes
Document responding to:	Clinical Commissioning Policy Proposition for selective internal radiation therapy (SIRT) in the treatment of chemotherapy refractory and intolerant, unresectable metastatic colorectal cancer (Adults)
Relevant CRG	Radiotherapy CRG

It is proposed that highly specialised products will go for period of public consultation.

Please select the consultation level that you consider to be most appropriate.

1 - changes that could reasonably be expected to be broadly supported by stakeholders - up to 6 week consultation

Do you have any further comments on the proposed changes to the document?

1. YES

If Yes, please describe below, in no more than 500 words, any further comments on the proposed changes to the document as part of this initial 'sense check'.

1. Page 23 – Typo - “five of less” should be “five or less”
2. Page 23 – clarification of inclusion criteria - 25% tumour to liver volume or less AND 5 or fewer liver tumours or 25% tumour to liver volume or less OR 5 or fewer liver tumours – the CtE data would support both groups being included equally.
3. The draft commissioning proposition supports only use of resin microspheres. The CtE data was predominantly related to resin microspheres (84% versus 16%) but the products were treated the same. No subgroup analysis was planned or carried out looking at the differences between the products and there is no evidence supporting a differential response between these products so this should be at the discretion of the treating clinician.
4. The overall reimbursement for the procedure causes concern. During the CtE programme Trusts were reimbursed £21,550 per course of SIRT. Pennington et al (2017) estimated that each course of SIRT cost approx. £14,248 to deliver. The current tariff reimbursement is unclear as an unbundled brachytherapy tariff is not available and the cost of the microspheres themselves has not been addressed. We are unsure how any Trust will be able to support delivery of SIRT, thus limiting access to this technology unless a national pricing framework for the microspheres is agreed.

Please declare any conflict of interests relating to this document or service area.

--